Quanterix Corporation (QTRX) stock analysis
Healthcare · Medical Devices
From the 10-K filed 2026-03-02
How it makes money
It sells sensitive diagnostic instruments and recurring consumables to research labs and biopharma firms, with profit driven by the size of its installed base.
The company provides ultra-sensitive protein detection platforms used in neurology and oncology. Revenue is generated through the sale of high-tech instruments and the essential consumables required to operate them. A significant portion of these earnings is recurring as customers must purchase these components to keep the machines functional. Additionally, it offers contract research services to academic and commercial institutions.
What protects it: the moat
Management claims its proprietary digital detection technology and scientific validation provide a competitive advantage.
The company relies on its Simoa platform's ability to detect proteins at extremely low concentrations, a capability it asserts is superior to standard analog methods. It further claims that its widespread adoption, evidenced by thousands of citations in scientific literature, protects its market position.
What could damage it
Reliance on a few large customers means that industry consolidation or reduced spending could permanently destroy its revenue base.
Because a substantial portion of its income is concentrated among a small number of clients, any decision by these entities to consolidate their operations or cut budgets directly shrinks the company's addressable market and disrupts its recurring revenue streams.
About Quanterix Corporation
Quanterix Corporation, a life sciences company in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, the company offers contract research and clinical laboratory testing services, including research and clinical trial testing, and lucent diagnostic services. The company primarily operates in the areas of neurology, oncology and immunology, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and sales force and distributors. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.